Stryker Corp.
Stryker Corporation (SYK)
Overview
Stryker Corporation is one of the world's largest medical technology companies, designing, manufacturing, and selling a broad range of surgical, orthopaedic, neurotechnology, and medical-surgical products used in hospitals and outpatient facilities worldwide. Headquartered in Portage, Michigan, Stryker traces its roots to 1941, when orthopedic surgeon Dr. Homer Stryker founded The Orthopedic Frame Company; it took its current name in 1964 and went public in 1979. The company is part of the S&P 500 and classified in Medical Devices/Healthcare, and it has grown into a roughly $25 billion-revenue (full year 2025) business with net earnings of about $3.2 billion and roughly 56,000 employees, selling products in more than 75 countries and touching an estimated 150 million patients per year.
What They Do & How They Make Money
Stryker makes money primarily by selling physical medical devices, implants, capital equipment, and increasingly software/robotics and associated services to hospitals and surgery centers. Revenue comes from two broad streams: (1) implants and disposable/single-use surgical products — artificial hips, knees, shoulders, trauma fixation hardware, surgical instruments, and endoscopy/energy devices — which are consumed or implanted with each procedure and recur as procedure volumes grow; and (2) durable capital equipment such as operating room tables, patient handling and transport systems, endoscopic camera/visualization systems, and its Mako surgical robotic platform, which are typically sold or leased to hospitals with follow-on service, software, and consumables revenue over the equipment's life. A growing and strategically important piece is "enabling technology" — robotics (Mako) and navigation systems that guide surgeons during joint replacement and spine procedures — which locks in hospital capital budgets and then pulls through higher-margin implant sales, since Mako systems are optimized for use with Stryker's own implants. Stryker also grows through an active M&A strategy, regularly acquiring smaller device makers to add new product categories (most recently a $4.9 billion acquisition of Inari Medical to enter peripheral vascular/thrombectomy, alongside a planned divestiture of its spinal implants business), which shifts its portfolio toward higher-growth technology areas over time.
Business Segments
Effective for fiscal 2026 reporting (with historical data recast), Stryker consolidated its reporting structure into two segments:
- MedSurg and Neurotechnology — The larger and faster-growing segment (about 62% of full-year 2025 revenue, roughly $15.6 billion, up nearly 16% year over year). It bundles: Instruments (surgical equipment and navigation systems), Endoscopy (visualization, communications, and energy systems for minimally invasive surgery), Medical (patient handling equipment, emergency medical equipment, intensive-care disposables, and clinical communication/AI-assisted virtual care software), Vascular/Neurovascular (minimally invasive stroke and venous thromboembolism treatment devices), and neurosurgical products for brain and skull-base procedures, plus orthobiologics and biosurgery products. This segment's growth has been boosted by recent acquisitions (e.g., Inari Medical) and strong demand in neurovascular and surgical technology.
- Orthopaedics — About 38% of full-year 2025 revenue (roughly $9.5 billion, up about 4% year over year). Covers joint replacement implants (hip, knee, shoulder), trauma and extremities products, and the newly created "Ortho Tech" business that pairs orthopaedic instruments with the Mako robotic-arm assisted surgery platform and other enabling technologies. This segment is more mature and grows more slowly than MedSurg/Neurotechnology, though Mako placements are a key growth lever.
Competitors
Stryker's competitive set differs by product line but overlaps heavily with the other large diversified medtech players:
- Orthopaedics (joint replacement, trauma): Zimmer Biomet, Johnson & Johnson MedTech (DePuy Synthes), Smith & Nephew, and Globus Medical/Enovis in spine and extremities.
- Surgical robotics/navigation: Intuitive Surgical (soft-tissue robotics, adjacent market), Johnson & Johnson (Ottava/Velys), Medtronic (Hugo, Mazor), and Zimmer Biomet (ROSA).
- MedSurg/endoscopy/medical equipment: Medtronic, Olympus, Karl Storz, Baxter International, Getinge, and Becton Dickinson.
- Neurotechnology/neurovascular: Medtronic, Johnson & Johnson (Cerenovus), Penumbra, and Integra LifeSciences.
Competitive Position
Stryker is widely regarded as one of the best-positioned companies in medtech, with a diversified, high-single-to-double-digit organic growth profile that outpaces most large-cap peers. Its Mako robotic-arm platform has become a genuine competitive moat in orthopaedics: hospitals that invest in a Mako system tend to standardize on Stryker implants for compatible procedures, creating a sticky, recurring revenue relationship that is difficult for a pure implant maker to dislodge. Scale advantages — a large, well-trained sales and clinical-support organization, broad manufacturing footprint, and deep regulatory/quality infrastructure — let Stryker cross-sell across its wide product range and support large hospital systems as a single vendor for multiple categories. Its consistent, disciplined "tuck-in" M&A strategy (dozens of acquisitions over the past decade) continually refreshes the portfolio with higher-growth technologies, exemplified by the 2025 Inari Medical deal moving Stryker into the growing peripheral vascular/thrombectomy space, while divesting slower-growth or commoditizing businesses like spinal implants.
Key risks include pricing pressure from hospital group purchasing organizations and increasing cost-consciousness in healthcare systems; product liability and litigation risk inherent to implantable devices (Stryker has faced significant hip and other implant recall litigation historically); regulatory risk from FDA and international device-approval processes, where delays can push back new product launches; and integration risk from its acquisitive growth strategy. Competitively, Stryker must continue to out-innovate larger, well-capitalized rivals like Johnson & Johnson and Medtronic in robotics and enabling technology, an area where all major orthopaedic and surgical players are racing to build comparable platforms — meaning Stryker's current robotics lead, while significant, is not guaranteed to persist without continued R&D investment.